Celldex Therapeutics, Inc.
CLDX · Nasdaq · USD · Market cap $2.2B · 198 employees
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price27.42 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.36x the price, above our 2.00x limit.
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 3.48)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 3.48, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Celldex Therapeutics, Inc. holds its Distribution at $27.42. Consolidating, no directional conviction, held for 66 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 66 days |
| Price at the screen | $27.42 |
| Valuation | N/A trailing · -6.66 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.03 |
Five Screens: CLDX's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.40% | Below 33% | Pass |
| Interest-bearing cash | 84.00% | Below 33% | Fail |
| Receivables | 5.30% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Celldex Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 84% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when CLDX's ethical verdict changes
Today CLDX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.36x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 14 covering, consensus Strong Buy. Average target +141%.
Antibody developer flashes fair value gap yet no opportunity
Picture a lab racing to craft monoclonal antibodies against severe autoimmune conditions. Celldex sits there with a stated fair value well above the share price, yet the opportunity rating stays none. Revenue has collapsed 98 percent, profit margins remain zero and return on equity is negative 49 percent, so the numbers give no reason to engage.
The ethical screen clears but that is not enough. Forward earnings sit at negative 7.9 times with an unknown moat and fifteen analysts offering no consensus rating. The gap to the median target of 54 dollars looks tempting on paper alone, yet the underlying business shows nothing that would change our stance.
Biotech pipelines carry binary risk and heavy cash burn. Without profits or revenue growth the firm may need repeated funding rounds that dilute holders further. Analysis, not advice.
| Forward P/E | -6.7x |
| EPS, trailing | -4.29 |
| EPS, forward | -4.21 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -49.5%not currently earning a positive return on equity |
| FCF yield | -7.01% |
| Debt to equity | 1.52a meaningful debt load worth watching |
| Current ratio | 10.97comfortably covers its short-term bills |
| Beta | 1.03moves a little more than the market |
| Short interest, float | 0.15% |
| 52-week range | 22.33 - 45.14 |
| Market cap | $2.2B |
| Employees | 198 |
CLDX-specific watchpoints · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review.
The framework has shifted from markdown to markup since the last review.
Earnings landed in this window.
The framework has shifted from distribution to markdown since the last review.
Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results Yahoo Finance · 11d ago
- Celldex Stock In Focus After Earnings Loss And Shelf Filing Yahoo Finance · 15d ago
- Celldex: Q3 Earnings Snapshot Yahoo Finance · 16d ago
- Celldex Reports Third Quarter Financial Results and Provides Corporate Update Yahoo Finance · 16d ago
- Celldex to Present at Upcoming Investor Conferences Yahoo Finance · 17d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $32.28 | -8.6% | · | $914 | -8.6% |
| 2 months | $32.24 | -8.5% | · | $915 | -8.5% |
| 3 months | $29.88 | -1.3% | · | $987 | -1.3% |
| 6 months | $27.94 | +5.6% | · | $1,056 | +5.6% |
| 1 year | $20.92 | +41.0% | · | $1,410 | +41.0% |
| 2 years | $34.64 | -14.8% | · | $852 | -14.8% |
| 3 years | $34.80 | -15.2% | · | $848 | -15.2% |
| 5 years | $31.04 | -5.0% | · | $950 | -5.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CLDX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.